Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

by · The Cerbat Gem

RxSight, Inc. (NASDAQ:RXST – Get Free Report) insider Ilya Goldshleger sold 3,100 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $49.79, for a total transaction of $154,349.00. Following the completion of the sale, the insider now directly owns 42,246 shares in the company, valued at $2,103,428.34. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ilya Goldshleger also recently made the following trade(s):

  • On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.64, for a total transaction of $156,984.00.
  • On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00.
  • On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,529.45.
  • On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total value of $154,318.00.
  • On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total value of $155,589.00.
  • On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,279.00.
  • On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
  • On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total transaction of $148,831.00.
  • On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00.
  • On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.

RxSight Stock Performance

Shares of RXST stock traded down $0.13 during mid-day trading on Monday, reaching $50.25. 324,504 shares of the company were exchanged, compared to its average volume of 468,027. RxSight, Inc. has a fifty-two week low of $20.66 and a fifty-two week high of $66.54. The company has a market capitalization of $1.86 billion, a P/E ratio of -49.26 and a beta of 1.20. The business’s 50 day simple moving average is $51.91 and its 200 day simple moving average is $53.67.

RxSight (NASDAQ:RXST – Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The business had revenue of $34.89 million during the quarter, compared to the consensus estimate of $32.33 million. During the same period last year, the firm earned ($0.40) earnings per share. The company’s revenue for the quarter was up 67.6% compared to the same quarter last year. On average, analysts forecast that RxSight, Inc. will post -0.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on RXST. Wells Fargo & Company cut their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Oppenheimer decreased their price target on RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. BTIG Research lifted their price objective on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Stifel Nicolaus decreased their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $60.14.

Read Our Latest Stock Analysis on RXST

Hedge Funds Weigh In On RxSight

Several large investors have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its position in shares of RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after buying an additional 207 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in RxSight by 3.2% in the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock valued at $473,000 after acquiring an additional 242 shares during the period. RiverPark Advisors LLC grew its holdings in shares of RxSight by 9.6% during the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock valued at $203,000 after purchasing an additional 297 shares during the last quarter. CWM LLC grew its holdings in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of RxSight by 5.0% during the 2nd quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock worth $467,000 after purchasing an additional 373 shares during the period. 78.78% of the stock is currently owned by institutional investors.

About RxSight

(Get Free Report)

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Featured Stories